Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FOLFOX for unresectable pancreatic cancer with germline BRCA pathogenic variant
jRCT1061230031Phase 2Recruiting
- Sponsor
- Yamaguchi University Hospital
- Start
- May 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, levoleucovorin and fluorouracil in pancreatic cancer (PC), sponsored by Yamaguchi University Hospital. Primary endpoint: 16-week progression-free survival. Started May 2023; status: recruiting.
02
Drugs
oxaliplatinlevoleucovorinfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT1061230031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061230031.